A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy (TH3RESA)
This study has been completed.
First Posted: August 18, 2011
Last Update Posted: October 12, 2016
Information provided by (Responsible Party):